Shah Millie B, Merchant Lubna, Chan Irene Z, Taylor Kellie
1 Food and Drug Administration, Center for Drug Evaluation and Research/Office of Surveillance and Epidemiology/Office of Medication Error Prevention and Risk Management/Division of Medication Error Prevention and Analysis, Silver Spring, MD, USA.
Ther Innov Regul Sci. 2017 Mar;51(2):232-236. doi: 10.1177/2168479016667161. Epub 2016 Sep 27.
This study aimed to provide a descriptive analysis of characteristics that are common among drug name pairs involved in name confusion medication errors.
We evaluated drug name pairs that contained at least one proprietary name from the Institute for Safe Medication Practices (ISMP) List of Confused Drug Names. For each name pair, we analyzed whether the following characteristics were present: (1) the same first letter, (2) a shared letter string of at least 3 letters, and (3) similarity in the number of letters. Additionally, we obtained the combined Phonetic and Orthographic Computer Analysis (POCA) score.
Ninety-nine percent of the drug name pairs reflected at least one of the 3 characteristics analyzed. Additionally, 75% of the names had a combined POCA score of ≥50%.
This descriptive analysis provides some insight into characteristics that may be associated with name confusion, which should be considered when formulating and evaluating proposed proprietary drug names.
本研究旨在对涉及药品名称混淆用药错误的药品名称对所共有的特征进行描述性分析。
我们评估了至少包含一个来自安全用药实践研究所(ISMP)混淆药品名称列表中商品名的药品名称对。对于每一对名称,我们分析是否存在以下特征:(1)首字母相同;(2)至少有3个字母的共享字母串;(3)字母数量相似。此外,我们还获得了语音和拼字计算机综合分析(POCA)得分。
99%的药品名称对反映了所分析的3个特征中的至少一个。此外,75%的名称的POCA综合得分≥50%。
这一描述性分析为可能与名称混淆相关的特征提供了一些见解,在制定和评估拟用的药品商品名时应予以考虑。